益佰制药股价下跌1.54% 上半年亏损收窄至1990万元

Core Viewpoint - Yibai Pharmaceutical is facing challenges due to product suspension and commercial bribery issues, impacting its stock performance and financial results [1]. Financial Performance - As of August 21, 2025, Yibai Pharmaceutical's stock price is 4.48 yuan, down 1.54% from the previous trading day, with a trading volume of 251 million yuan [1]. - The company reported a revenue of 993 million yuan for the first half of 2025, a year-on-year decrease of 14.99%, and a net loss attributable to shareholders of 19.90 million yuan, although the loss margin has narrowed compared to the same period last year [1]. Business Operations - Yibai Pharmaceutical's main business includes pharmaceutical manufacturing and medical services, with key products comprising traditional Chinese medicine preparations, chemical drugs, and medical services [1]. - The company plans to acquire the remaining equity of its controlling subsidiary for 80 million yuan to consolidate its assets [1]. - The sales of its pediatric cough syrup have been suspended due to production defects, but this product contributes a small portion to overall revenue, thus the expected impact on performance is limited [1]. Capital Flow - On August 21, 2025, the net outflow of main funds for Yibai Pharmaceutical was 23.71 million yuan, while there was a net inflow of 45.90 million yuan over the past five days [2].